The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
Pierson
Charon A
CA
cpierson@aanp.org
Epstein
Benjamin J
BJ
Roberts
Mary Ellen
ME
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D055317:Evidence-Based Practice; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008019:Life Style; D009722:Nurse Practitioners / Q000458:organization & administration; D009730:Nursing Assessment; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011320:Primary Health Care; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D040242:Risk Reduction Behavior; D012720:Severity of Illness Index
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors